Overview
- 8 inspections across 8 sites are on record.
- 4 Form 483 observations are attributed to this investigator.
- Most recent recorded activity is 2022-11-16.
At a glance
Inspections
8
Sites
8
Observations
4
Career since
Nov 2018
Recent inspections
Most recent inspections in the published record.
| Site | Date | Category | Form 483 |
|---|---|---|---|
| XERIS PHARMACEUTICALS INC | 16 Nov 2022 | Human Drugs | |
| Daiichi Sankyo, Inc. | 15 Jul 2022 | Human Drugs | |
| AstraZeneca Pharmaceuticals LP | 27 Oct 2020 | Human Drugs | |
| Ming-Shen Dai, M.D., Ph.D. | 27 Sep 2019 | Human Drugs | On file |
| Puma Biotechnology, Inc. | 24 May 2019 | Human Drugs | View 483 → |
Sites inspected
XERIS PHARMACEUTICALS INCChicago, United States1 insp.
Daiichi Sankyo, Inc.Basking Ridge, United States1 insp.
AstraZeneca Pharmaceuticals LPGaithersburg, United States1 insp.
Ming-Shen Dai, M.D., Ph.D.Taipei City, Taiwan1 insp.
Puma Biotechnology, Inc.Los Angeles, United States1 insp.
Co-investigators
Investigators who share inspections with this person.
Lynda L Lanning1 shared
Jeanne J Thai1 shared
Michael Serrano1 shared
Lee Hong Pai Scherf1 shared
David L Chon1 shared
Ni A Khin1 shared
Karen M Cooper1 shared
Corrine M Carter1 shared
Richard W Berning1 shared
Angela Shepas1 shared
Full investigator report
Get the verbatim findings behind Yangmin Ning's 4 observations
Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.
- New inspections and Form 483s, mapped to the CFR citation
- Warning letter outcomes, and the citation patterns they repeat
- Their co-investigators, so no surprises about who shows up on site